Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 1/20 | 0.44 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897119 | 0.84 | L3MBTL3 (0.48) | CCKBRLPAR5HPGDLMNATSHR | |
| SCHEMBL3895784 | 0.81 | HPGD (0.53) | HPGDLMNATSHRALDH1A1MEN1 | |
| SCHEMBL3899778 | 0.79 | HTT (0.60) | CCKBRHPGDLMNATSHRALDH1A1 | |
| SCHEMBL3898289 | 0.78 | HPGD (0.67) | HPGDLMNATSHRALDH1A1MEN1 | |
| SCHEMBL5097993 | 0.78 | NPC1 (0.56) | ALDH1A1MEN1KMT2AHTTNPSR1 | |
| SCHEMBL3901908 | 0.78 | ALDH1A1 (0.56) | CCKBRHPGDLMNAALDH1A1MEN1 | |
| SCHEMBL3911601 | 0.78 | MAP2K2 (0.45) | CCKBRHPGDLMNATSHRALDH1A1 | |
| SCHEMBL4506300 | 0.78 | MAP2K2 (0.45) | CCKBRHPGDLMNATSHRALDH1A1 | |
| SCHEMBL3901241 | 0.78 | HPGD (0.51) | HPGDTSHRALDH1A1MEN1KMT2A | |
| SCHEMBL4506867 | 0.78 | ALDH1A1 (0.56) | CCKBRHPGDLMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | claimed |
| US-7550492-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-06-23 | — | — | US | disclosed |
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-11-29 | — | — | US | disclosed |
| US-7241759-B2 | Benzo[1,2,5]thiadiazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276016-A1 | BENZO[1,2,5]THIADIAZOLE COMPOUNDS | CCKBR, CCKAR, GIPR | CCKBR 1/4885LPAR5 2349/4885HPGD 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.